StemCell Therapy

ST. PETERSBURG, Fla., Feb. 8, 2021 /PRNewswire/ -- Stemedix, Inc. is excited to announce its research collaboration agreement with the University of South Florida. This partnership will facilitate advancements in regenerative medicine offerings while helping provide a more precise and personalized approach to existing and future treatment options.

Stemedix, Inc. and the University of South Florida will partner together in an effort to advance the validity of stem cell treatments and overall patient outcomes. Further, this research will broaden the understanding of the full ability of current umbilical cord tissue products in the market and how they scientifically improve cell activity in the regenerative and healing process.

The goal of this collaboration is to collect the appropriate data to create targeted and enhanced protocols that may then be used under a Research IND (investigational new drug) to achieve FDA approval.

"We are excited to be a contributing part of the research and advancement efforts to create protocols that will provide optimal patient outcomes. The groundwork we are doing today will help to create advanced targeted therapies to present to the FDA for approval," said Fred Palmer, director of operations, at Stemedix, Inc. "Stemedix is proud to be partnering with this prestigious university to bring about exciting opportunities in the field of regenerative medicine for patients seeking an alternative option that will address their needs personally."

Stemedix, Inc. has rooted in the foundation that regenerative medicine is the future and will continue its path of advancement for the medical industry in the service of their patients. Parallel to this partnership, they have established an actively updated blog site with scientific summaries of industry studies led by their Ph.D. team at https://www.stemedix.com/blog

Stemedix, Inc. is a Regenerative Medicine and Wellness provider headquartered in St. Petersburg, FL with other locations throughout the U.S. and Costa Rica. Stemedix was founded to provide access to patients seeking alternative options for their degenerative, chronic pain, or autoimmune condition. With an eight-year footprint in the industry of Regenerative Medicine, Stemedix has maintained its authenticity as an ethical and compassionate provider by focusing on patients' safety and positive end to end experience while following science in an effort to create optimal treatment outcomes. The Stemedix difference is the quality of our care coordinators, providers, and understanding of the importance of having a worry-free and safe experience.

To speak to one of our Care Coordinators call 800-531-0831 or visit our website http://www.stemedix.com

Related Images

stemedix-inc.png Stemedix, Inc

university-of-south-florida.jpg University Of South Florida USF Logo

SOURCE Stemedix, Inc.

Visit link:
Stemedix and the University of South Florida Join Forces - PRNewswire

Exosome therapeutic Market Report Provides Future Development Possibilities By Key Players, Key Drivers, Competitive Analysis, Scope, And Key Challenges Analysis. The Reports Conjointly Elaborate The Expansion Rate Of The Industry Supported The Highest CAGR And Global Analysis. This Report Providing An In Depth And Top To Bottom Analysis By Market Size, Growth Forecast By Applications, Sales, Size, Types And Competitors For The Creating Segment And The Developing Section Among The Exosome therapeutic Market. Market Expansion Worldwide With Top Players Future Business Scope and Investment Analysis Report

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

View original post here:
Exosome therapeutic Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel Newspaper - KSU...

In this credible Exosome therapeutic Market report, a study about market overview is performed by considering market drivers, market restraints, opportunities and challenges. Moreover, this report contains significant data, current market trends, market environment, technological innovation, upcoming technologies and the technical progress in the allied industry. This is the most relatable, exclusive, and commendable market research report formulated by focusing on definite business needs. The competitive analysis conducted in this report covers strategic profiling of key market players, their core competencies, and competitive landscape. To gain meaningful market insights and thrive in this competitive market place, this Exosome therapeutic Market research report plays a key role.

Exosome therapeutic Market report also makes available major statistics on the market status of global and regional manufacturers and is a supportive source for companies and individuals interested in the industry. The careful efforts accompanied with integrated approaches gives an output of such excellent market research report that drives the decision making process of the business. This report endows with a profound overview of product specification, technology, product type and production analysis by considering most important factors such as revenue, cost, and gross margin. With this influential Exosome therapeutic Market analysis report businesses can successfully make decisions about business strategies to achieve maximum return on investment (ROI).

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

The rest is here:
Exosome therapeutic Market to Deliver Prominent Growth & Striking Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 - The...

Whats the secret to living a healthy, long life? It was the big question on Daniel Kennedys mind when he set out to direct and produce his (aptly named) docu-series, Healthy Long Life. Besides wanting to know to inform his own personal habits, he had a stake in finding the answer for professional reasons too: As the CEO of Oasis of Hope Hospital in Tijuana, Mexico, helping people live well into old age is one of his great missions.

Kennedy decided to travel all over the world (this was pre-pandemic) to see if he could find the answer by learning from the worlds leading longevity experts. I was interested in going to the longevity capitals of the world, Kennedy says. Of course the research on Blue Zones caught my attention, but there are many other places where [living to be over 100 in good health] is common so I wanted to go other places too.

As of January 2020, life expectancy in the U.S. was 78.7 years, and is projected to increase to 85.6 by the year 2060 (although the ongoing coronavirus pandemic may affect that estimate). We have modern medicine to thank for this, but what modern medicine has failed to do is add more healthy years to life, Kennedy says. We are living longer because we are able to overcome infections and treat disease, but what modern medicine doesnt do as well is prevent disease. With that in mind, Kennedy says he wanted to learn from cultures outside the U.S. that value other healing traditions.

While he did visit a few Blue Zones regionsspecifically Sardinia, Italy and Okinawa, Japanhe traveled far and wide to unsung longevity hotspots too. So, did he discover the secret to living a healthy, long life? Kennedy says he definitely came back from the trip wiser. Here are some highlights of what he learned about longevity from five different countries around the globe.

Kennedy traveled to India to learn more about Ayurveda, a holistic medicine practice that has been around for over 5,000 years, and its potential to increase longevity. He spoke with some of the countrys leading health experts, including non-invasive cardiology pioneer Bimal Chhajer, MD, and spice expert Deepa Krishnan, to learn about how Ayurvedic principles play primary roles in many Indian peoples lives.

Traditionally, Ayurvedic practices are used to bring balance to the body based on each persons individual dosha (their emotional and physical constitution). Ayurvedic physicians and healers use your dosha to help identify, customize, and prescribe lifestyle changes and remedies that aim to balance your energies, prevent disease, and preserve health. In this way, doshas are used to personalize medicine. For example, a pitta dosha is linked to premature aging more than those with a kapha dosha. Ayurvedic healers in India use information like this to inform their health advice.

Kennedy also experienced the benefits first-hand of the pungent spices so prominent in Indian food (and in many cases, important to Ayurvedic remedies). Turmeric, ginger, nutmeg, and saffron, are just a few of the common spices used in Indian cooking that are linked to lowering inflammation, the root cause of chronic diseases and cognitive decline. In this way, what you eat can be directly tied to disease prevention and living a longer, healthy life.

What I learned from Dr. Chahhajer is how food is being used to promote healing, Kennedy says. He also works with patients in areas of anger management, forgiveness, and stress management. All of these ways, he says, inspire more balance, which he believes is essential to longevity.

Watch the video below to learn more about how turmeric is good for longevity:

Since Kennedy is the CEO of a hospital in Mexico (and he himself has Mexican roots), he decided to see what he could learn in his own country, too. In Mexico, he spoke with Mayan shaman Bartolome Poot Nahuat, Pedro Batiz, the co-founder of Divine Flavor, and various centenarians about their lives and practices.

Like in India, Kennedy says living a life of balance was something the experts he encountered spoke of, even if they didnt use Ayurvedic principles to inspire it. Kennedy says what he learned in Mexico was to be present. [Many of the people I met] dont focus on yesterday or tomorrow, they focus on today, he says. For many, being part of a close-knit extended family and community are key; life is lived together, not alone. To this point, a2019 United Nations report found that living with a child or extended family members was the most common living arrangement for elderly adults in Latin America.

Like Indian cuisine, Mexican cuisine traditionally uses lots of health-promoting spices. Cayenne pepper, garlic, cilantro, chipotle powder, and cinnamon are all common spices in Mexican cuisine that are linked to warding off chronic disease by lowering inflammation.

Watch the video below to learn more about the health benefits of garlic:

When you look at Israel on a map, its right in the middle between Africa, Asia, and Europe, so all the traders from these regions crossed through Israel and brought their healing traditions along, Kennedy says. Because of this, Israel is really a melting pot of wisdom from all three of these continents.

Kennedy says the biggest longevity lesson he learned from Israel was using food as medicine. (Yep, food, once again!) The food in Israel is so incredibly fresh. Fresh vegetables, fruit, and fish are a huge part of the culture. He learned first-hand about the longevity-boosting properties of the Mediterranean diet from experts including Ronit Endevelt, Ph.D., the director of the nutrition division for the Israeli Ministry of Health & School of Public Health and Haifa University, Ayala Noy Meir (a professional olive oil taster), and Uzieli Hazay, who runs the Etrogman juice bar in Tel-Aviv that sells many natural remedies.

Hundreds of studies have linked the Mediterranean dietwhich advocates for lean proteins, whole grains, seafood, and plenty of vegetablesto longevity. There have been studies upon studies that have shown that the Mediterranean diet can lower the incidence of heart disease by as much as 70 percent, Suzanne Steinbaum, DO, a cardiologist and the director of womens cardiovascular prevention, health, and wellness at Mount Sinai Hospital in New York City, previously told Well+Good. Its why the eating style popular in Israel (and other parts of the Mediterranean) is so often recommended by doctors here in the U.S.

Watch the video below to learn more about why the Mediterranean diet is linked to longevity:

The infamous China Study, one ofthe largest comprehensive studies of human nutrition ever conducted, is what drew Kennedy to China. The study, which collected data from 6,500 adults in 65 prefectures in China over the course of 20 years, was a partnership between Cornell University, Oxford University, and the Chinese Academy of Preventative Medicine. Kennedy spoke directly with lead researcher T. Colin Campbell, PhD, who wrote the book The China Study($15) to learn more about its findings.

Once again, Kennedy says one of the biggest lessons he learned was through food. Dr. Campbell shared with him that one of the major takeaways of the China Study is how plant-based eating can protect against chronic diseases, including cancer and heart disease. I saw first-hand what plant-based eating looks like in China by visiting the market, Kennedy says. I was amazed at the incredibly vast variety of vegetables there were. In the U.S., you might find three or four different types of apples and a few different types of mushrooms, but in China, I had seven different mushrooms in one meal and they have many more different types of apples. I saw carrots in a huge variety of colors! (Gastroenterologist Will Bulsiewicz, MD, previously told Well+Good that eating a wide variety of plants was the number one best thing you can do for your gut, which in turn affects your health as a whole.)

Kennedy also learned about how Traditional Chinese Medicine (TCM) is ingrained in many peoples daily lives in China. Similar to Ayurveda, TCM focuses on bringing balance to the body. One principle of TCM is qi, which is life energy that runs through the body. TCM doctors and healers often focus on ways to maintain qi through herbs, acupuncture, meditation, and movement. TCM is used prominently to prevent and treat disease and is a cornerstone of longevity in China.

Japan is home to one of the seven Blue ZonesOkinawabut Kennedy also spent time in Tokoyo and Kyoto meeting experts including Akitsugu Moriyama, the president of the Cancer Control Society of Japan; Mikako Harada, MD, an oncologist and expert in anti-inflammatory nutrition; and Takafumi Kawakami, a mindfulness expert and the deputy head priest of Shukoin Temple in Kyoto, Japan.

Kennedy says that the importance of mindfulness was a lesson he took home from Japan, something he saw through the elaborate matcha tea ceremonies that are held as well as in the types of exercises that are commonly practiced in the country. Japan is also a culture that really celebrates growing older as opposed to in the West where its something thats often viewed as a negative, he adds. (Just take Respect for the Aged Day, a national holiday in Japan where the elderly are given gifts from their local government and families gather together to honor their older loved ones.) Age-specific terminology is used to address older people. This complex of linguistic and social practices contributes to the acceptance and appreciation of old age, the paper reads. Feeling appreciated and valued can lead to feeling happy, which is directly linked to longevity.

While all the places Kennedy visited while filmingHealthy Long Life have their own unique ways of life, there are a few commonalities. Living a balanced life and finding ways to manage stress is key. So is eating lots of plants and flavorful herbs. Being connected to others is another way of living each culture valued. So maybe there isnt One Big Secret to living a healthy, long lifebut rather a few habits and traditions to cultivate daily.

Oh hi! You look like someone who loves free workouts, discounts for cult-fave wellness brands, and exclusive Well+Good content. Sign up for Well+, our online community of wellness insiders, and unlock your rewards instantly.

Follow this link:
Experts Unpack Longevity Secrets From 5 Different Cultures Around the Globe - Well+Good

If you were to describe LeBron James to a person who had never seen a game of basketball before, or no awareness of the sport, I am not sure you would be able to do it. Where do you start?

Oh, here's a guy built like an upright cargo jet with the footspeed of a wide receiver, the grace and poise of a gymnast and the deftness of touch of a sculptor. He has the same calm intelligence as a chess grandmaster, or a Number 10.

He's also 36, in his 18th season and has only ever suffered one major injury - a groin issue in 2018/19 that kept him out for... 17 games. That's it. That's the longest amount of time he's ever missed.

Beyond that, he's been as ever-present in the NBA as the hoops and the hardwood, averaging roughly 27 points, 7 rebounds and 7 assists season in and season out. For some players, that stat line would represent the best night of their careers. For LeBron it's the minimum expectation, the same way you do not question whether the sun will rise in the morning. You know it will. You rely on it to.

It's something of a running joke now that he has not slowed down given, you know, the natural biological consequences of ageing and the fact James has played over 60,000 minutes of professional basketball, including playoffs.

To put that into perspective, you can combine the regular-season minutes of Lou Williams (34, 17th season) and J.J. Redick (36, 16th season), two other league stalwarts, and you would still have less than LeBron's regular-season total.

In fact, over the past three games LeBron has averaged 40 minutes and played four overtimes. The Lakers have won all three, including Wednesday night's 114-113 defeat of the Oklahoma City Thunder in which James hit the crucial three-pointer to send the game to an extra period, before then making a clutch steal on an inbounds play with four seconds remaining to secure the win.

Once again: this man is 36, in his 18th season, having played over 60,000 minutes in the NBA. There are paintings, fine wines, listed buildings and BitCoin traders envious of how LeBron James is ageing.

Yet, typically when we talk of an athlete's longevity, consistency and endurance, it usually comes at the cost of something else: the genuine ability to thrill. Take James Milner and Gareth Barry from the world of football for instance, two metronomes of the modern game but players who did not so much set the world alight as slowly and continuously drill right through to its core.

While they were undoubtedly exciting, dynamic and fearless in their youth, their permanence is what came to define them. The same for the likes of Tim Duncan, Jason Kidd, Ray Allen, Paul Pierce and Andre Iguodala in basketball. These are players we probably remember not for doing absurd things well into their 30s, but simply for still being there. Over time that tends to take on a remarkable quality in and of itself.

In our mind's eye we picture them as the grizzled veterans they became rather than the baby-faced destroyers of worlds they all once were during their ascendency.

LeBron James is different in many ways, but most startling is not that he can still do the things he has always done, from bulldozing straight through opponents to the rim or leaping out of the building to swat a shot into the rafters.

Most startling of all is that - somehow - he is still finding ways of improving on something already pretty close to basketball perfection.

This is probably the right moment to mention that LeBron is now one of the best snipers in the league, canning 39 per cent of his seven attempted threes per game. Those are almost Klay Thompson-level numbers. As per StatMuse, he is also averaging more points, rebounds, minutes, less turnovers and better field-goal, three-point and free-throw percentages than last season.

At what point do you give up waiting for the slump to come and just accept that this is it now, for eternity? That in a billion years when the Earth's surface heats, the oceans evaporate and all other life ceases to exist, only then will LeBron stop scoring 27 points a night, threading eye of needle passes and orchestrating another odd-parts and loose ends championship contender.

Tom Brady, understandably, has been the major talking point in the sporting world this week after winning his seventh Super Bowl at the age of 43. The most tiresome debate imaginable has once again reared its ugly head as the clickbait sites ask once and for all, until next month, who is the GOAT of the GOATs, the champion of champions. That misses the point of sport entirely. Brady's feats are staggering precisely because you cannot feasibly compare them to anything else that has happened before, in any sport, or even in any other aspect of life.

The same goes for LeBron. His career exists as a refutation of accepted truths. Of what the human body can do and what it can't. How long it can go on for. To contextualise him is impossible. You might wonder what the point is. Precisely that.

This is just another article, on another day, the morning after the night before when LeBron James put up 25 points, 6 rebounds and 7 assists and won a game of basketball. Again.

Originally posted here:
LeBron James' longevity and consistency will define him in the end as Los Angeles Lakers push for another title - Sky Sports

The first thing I decided to make was an antioxidant-rich beverage filled with cranberries, red currants, cherries, raspberries, lemon, and honey. I mixed those ingredients in the food processor, then added the concoction to hot water. Not only is the drink delicious, but it's also a simple way to increase your intake of immune-supporting vitamin C.

For the first few days, I didn't have much of an appetite (though I did retain my sense of taste and smell), so I opted for nutrient-rich and soothing drinks instead of solid food.

Along with the berry beverage, I also drank hot ginger tea with lemon, turmeric, and honey.Turmeric and ginger are high in anti-inflammatory properties, while hot water with honey also has a range of soothing health benefits.

For protein and gut support, I drank bone brothand when my appetite allowed for it, I'd use the broth as a base for vegetable soup containing blended leeks, broccoli, onions, herbs, and spices.

After the first three days, I continued drinking tea and incorporating berries and other antioxidant-rich foods into my diet. I also started transitioning back to my traditional everyday diet of nutrient-dense meals, with protein like chicken and fish.

View original post here:
I'm A Longevity RD & Here's How I Took Care Of Myself When I Had COVID-19 - mindbodygreen.com

News

Elizabeth Francis recently celebrated her 111th birthday.

(KTRK via CNN)

HOUSTON (KTRK) -- It's no longer unusual to know or hear about someone who's at least 100 years old these days. In fact, there were more than 90,000 people in the U.S. who were over 100 years old in 2020, according to the Census Bureau.

But a Houston woman has gone 11 years past the century mark.

Elizabeth Francis is now an incredible 111 years old. When asked her secret to longevity,she said: "The Lord just blessed me ... I say, 'Thank you Lord' when I wake up in the morning, and I thank Him when I go to bed."

ABC13 was there last year whenFrancis turned 110. She even had Mayor Sylvester Turner asa special guest at her party.

Francis was born in Louisiana in 1909. The Houstonian celebrated her 111th birthday on Saturday.

Francis gets proclamations from the city and state every year she reaches another milestone. As for what she eats to stay healthy, her response is: "Everything."

"No, I'm not on a diet," she said. "I just eat what I feel like eating, what I know I like."

Francis lives with her daughter, who is 92 years old. Her granddaughter, Ethel Harrison, keeps a watchful eye on both of them. Harrison said people don't believe her when she tells people her grandmother's age.

Harrison has her own theory about why her family members live so long. Francis's oldest sister lived to be 106, and her baby sister lived until she was 95.

"I think for them, it was the food that they ate," Harrison says. "They cooked everything, and it was fresh. My grandmother had a garden."

But there's a surprising twist to this story. Francis is not only one of the oldest people in Texas, she also worked at Channel 13 in the 1970s. She recently reconnected with old friend ABC13 anchor emeritus Dave Ward via Facetime to catch up on some memories.

Ward recalls when Francis ran the coffee shop, and remembered her for always closing on time.

When a former mayor wanted to order after close, Ward said, "One of the managers walked down to the coffee shop and said, 'The mayor would like a hamburger.' Miss Elizabeth said 'The grill is closed, the mayor don't need no hamburger.'"

Francis said, "I say what I want when I want."

Her life continues to be full these days thanks to her place of worship, Good Hope Missionary Baptist Church, and her family.

In addition to her daughter, she also has three grandchildren, four great-grandkids, and two great-great-grandsons.

The-CNN-Wire & 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Link:
111-year-old Houston woman shares secrets to longevity - - KTEN

Those albums helped lay the foundation for Cordaes own art and their influence on his musical DNA is all too apparent across the 15 tracks of his lauded debut. Released in summer 2019 via Atlantic, The Lost Boy resonated with a bevy of fans because of its contemporary approach to hip-hops classic elements. And while the project impresses with slick punch lines and heavy soul samples, its the storytelling that brings you back time and again. Much like his predecessors, Cordae showed a penchant for connecting with his audience by addressing his own demons and making them feel universal.

On Family Matters Cordaes vocals are buoyed by an uplifting bassline while he bares all, sharing the stories of family members grappling with domestic violence and substance abuse. On Thousand Words, the 23-year-old emcee frames our generations over-reliance on social media and the warped perception of reality that can result. The transparency that anchors his songwriting isnt employed without intention. Thousand Words, along with others on the album, he explains, were written from a real place. Fans can connect to it and it can help them, you get what I'm saying? It can inspire them to let them know, it's okay to not come from the best neighborhood. It's okay not to grow up having everything. It's okay to have family issues, that's normal.

His comment points to what really sets Cordae apart from his contemporaries -- an unflinching appreciation for the weight his pen holds if used for something greater. Its that awareness that placed 18-year-old Cordae at the center of a 2016 Black Lives Matter protest in Washington, D.C. In the video recently posted to his Instagram account, Cordae freestyles over a megaphone, his words moving the crowd of hundreds with a spirited plea, Please expose the truth to the world on a global view.

To this day, Cordae doesnt necessarily consider himself an activist. Instead, he clarifies, Im just always going to do what I feel is right and speak on what I believe in strongly. As such, it was no surprise to see Cordae last summer at peaceful demonstrations protesting the killings of George Floyd and Breonna Taylor, not because it was a shot at an Instagrammable moment, but simply, because it felt like its where he should be. It's not even a black or white thing, it's just right and wrong. He pauses for a moment before questioning, How can you not see what's going on in the world to Black people all around? I empathize with that.

Last August, Cordae channeled that empathy into a politically-charged feature on Stevie Wonders triumphant protest record, Cant Put It In the Hands of Fate, rapping: Mass confusion, people in power commit collusion/indoctrinated students, Im the leader of the movement/takes lifetimes, trying to duck the school-to-prison pipeline/disenfranchised, its amazing Im in my right mind.

Cordae might be unsure to what degree his next album will touch on social justice or 2020s bleak realities but he knows one thing for certain -- the quarantine-induced self-reflection hes engaged in will be a creative north star. Musics global shutdown offered Cordae the time to read, write and reflect in a way he hasnt been able to back to back years on the road. Hes not the same artist or person that he was when he released his debut and he wants his sophomore release to reflect that growth. It's a completely separate idea than The Lost Boy. It's not going to be a Lost Boy Two.

More:
With a Pair of Grammy Nominations in His Rearview, Cordaes Focus is Longevity - Billboard

researchers tested for options to power districts, including commercial and residential propertiesThough the Earths deeper layers have been raging at thousands of degrees for billions of years, new research involving Florida Tech has shown that tapping into that heat to produce geothermal heating for urban regions on the surface has a far, far shorter lifespan. (Florida Tech image)

BREVARD COUNTY MELBOURNE, FLORIDA Though the Earths deeper layers have been raging at thousands of degrees for billions of years, new research involving Florida Tech has shown that tapping into that heat to produce geothermal heating for urban regions on the surface has a far, far shorter lifespan.

Florida Tech astrobiology assistant professor Manasvi Lingam, along with Alto University researcher Eero Hirvijoki and University of Western Australia researcher David Pfefferl, recently published the paper, Longevity and power density of intermediate-to-deep geothermal wells in district heating applications in The European Physical Journal Plus.

The team explored how practical it to use geothermal heating in northern, colder latitudes, places like Boston, Toronto London and Helsinki, Finland.

The researchers tested for options that can power districts, including commercial and residential properties, not small-scale systems.

By examining the average amount of power requires per unit area for a city, the team has an idea of what will be required to power these places, thus helping guide their geothermal extraction research.

They have found that geothermal energy, after working well initially, weakens until after a generation or maybe a half-century, it becomes generally ineffective. This decline is due to shifts in the temperature gradient, a key element to geothermal heating.

Geothermal energy works by putting a pipe deep enough into the ground to tap into a warmer layer.

That could be 30 feet down, it could be hundreds of feet or even deeper. Using water or another fluid, that heat is brought toward the surface, where the temperatures are cooler.

These temperature differentials power the geothermal heating of cities and towns, and the gradient in temperature contributes to the energy that can be extracted.

However, over time, the warmer bottom region begins to cool down, and the upper regions warm up, causing the temperature gradient to slowly decrease, Lingam and the researchers found. The more the gradient declines, the less amount of heat can be extracted.

An option explored by the team is the use of multiple pipes, with the principle of taking advantage of extracting heat from different spatial locations and distributing it accordingly.

With the pipes extracting heat, temperatures would avoid becoming homogenous, thus allowing for the machines to run off the heat.

While Lingam noted this procedure would help to some degree, it would only be a short-term solution, as the temperature gradient would become homogenous vertically and horizontally.

This could work for a few decades, maybe even 40-50 years, but it wouldnt be continuously effective for more than a century or thereabouts, Lingam said.

They will need to need to start divesting off geothermal energy then more to solar or other forms of renewable energy.

CLICK HERE FOR BREVARD COUNTY NEWS

See original here:
Florida Tech Researchers Discover Geothermal Heating May Have Limited Longevity on Urban Regions - SpaceCoastDaily.com

Exercise is longevity's lifeblood because it wards off numerous chronic diseases, such as heart disease. What's more, you don't have to do much exercise to unlock the benefits. Research suggests walking every day can extend your lifespan.

Several studies have linked the mild intensity exercise to longevity but a study published in the British Medical Journal (BMJ) examined the association between time spent walking and life expectancy.

The authors followed up 27,738 participants aged 40 to 79years and prospectively collected data on their survival covering a 13-year-period.

The researchers found participants who walked one hour per day had a longer life expectancy from 40years of age than participants who walked less than onehour per day.

In addition to their longer life expectancy, participants who walked one hour per day required a lower lifetime medical expenditure from 40years of age than participants who walked less than an hour per day.

READ MORE:How to live longer: Tea with a slice of lemon could reduce cancer risk and boost longevity

In their concluding remarks, the researchers said: "Encouraging people to walk may extend life expectancy and decrease lifetime medical expenditure, especially for men."

Evidence suggests it is not only the duration of walking that counts but also the pace.

People who have a faster walking pace outlive those who walked more slowly, according to researchers who monitored the walking habits and deaths of nearly 475,000 people, most of whom were in their 50s at the start of the study.

Brisk walking was defined by researchers as walking at least three miles per hour, or 100 steps a minute.

DON'T MISSSouth Africa variant symptoms: The 15 possible signs[TIPS]Rice water for hair growth: Does it make hair grow?[ADVICE]Why Captain Moore did not take vaccine[INSIGHT]

It is worth nothing that walking pace was self-reported by participants, who were asked to indicate whether they walked at a slow pace, steady/average pace, or brisk pace.

The study, published in Mayo Clinic Proceedings, found that participants with brisk walking paces had longer life expectancies across all categories of body mass index (BMI).

BMI is a measure of body fat based on height and weight that applies to adult men and women.

The survival is the same for fast walkers for a wide range of body mass index, from 20 to 40, Dr. Francesco Zaccardi, a clinical epidemiologist at the University of Leicester in the United Kingdom and the studys lead researcher, told Healthline.

This result indicates that physical function is a stronger determinant of longevity than body mass index, and also people with high body mass index but with a good fitness may survive longer."

Conversely, participants with slower walking paces had shorter life expectancies across all categories of BMI.

Researchers reported that women who walked more quickly had a life span of about 87 years compared to 72 years for women who walked slowly.

Men who walked quickly had a life span of about 86 years compared to 65 years for men who walked more slowly.

Thats a 15-year average difference for women and a 20-year average difference for men.

Eating a healthy, balanced diet is an important part of maintaining good health, and can help you feel your best.

The Eatwell Guide shows that to have a healthy, balanced diet, people should try to:

"If you're having foods and drinks that are high in fat, salt and sugar, have these less often and in small amounts," adds the NHS.

See original here:
How to live longer: Walking every day promotes longevity - the amount you need to do - Express

Longevity swap pricing is expected to remain attractive through the coming year, as reinsurance capital to support large pension risk transfer deals remains abundant and slower mortality improvements feed into reinsurance pricing, according to Willis Towers Watson (WTW).After a busy year in 2020, when the market for longevity swaps and longevity risk transfer hit forecasted levels of activity and we listed just over 24 billion of longevity swap deals in our Directory, WTW is forecasting market conditions to remain conducive for the year ahead.

One of the drivers for this has been a general slowing in mortality improvements, the company explained, something that now could be exacerbated further by the COVID-19 pandemic and how that effects mortality rates.

Even before the pandemic hit, the slowdown in mortality improvements seen in recent years has been factored into the reinsurance pricing offered to support longevity swaps, WTW explained.

The result, is the lowest pricing relative to pension scheme reserves on record, the company noted.

On top of this, increasing competition in the market for longevity reinsurance deals is also helping to pressure pricing and keep reinsurers keen.

With the end result being the driving down of longevity swap and bulk annuity pricing, as well as pricing of capacity for pure longevity reinsurance deals, something WTW believes is set to persist.

As a result, the broker expects 2021 could see 25 billion of UK longevity swaps.

Ian Aley, Managing Director in Willis Towers Watsons Transactions team, explained, The pensions de-risking market has proved itself to be incredibly resilient and, while uncertainty will remain in 2021, we dont see this denting the desire and ability for pensions schemes to complete risk management transactions.

It remains to be seen what impact COVID-19 will have on longer term expectations for mortality rates. For many schemes, the market pricing of longevity will currently look very attractive relative to their funding reserves. We therefore expect schemes will continue to look to lock into assumptions which are affordable against their current funding target to reduce future uncertainty as part of their wider hedging programmes.

The rest is here:
Longevity swap pricing to remain attractive in 2021: WTW - Artemis.bm

Sportico is proud to partner with The Harvard Sports Analysis Collective, a student-run organization dedicated to the quantitative analysis of sports strategy and management, to bring our readers the excellent work coming from some of the brightest young minds in the country.

In a year marked by so much uncertaintyeven far beyond a certain 43-year-olds future as a professional quarterbackone constant has remained: Tom Brady is playing in the Super Bowl.

Over 21 years in the league, there isnt much he hasnt achieved. A 14-time Pro Bowler, three-time MVP, and six-time Super Bowl champion, Brady has at one time or another led the league in touchdowns, passing yards, expected points added, defense-adjusted yards above replacement, total quarterback rating, passer rating and any other statistical category you can conceive. Hes been recognized as the Offensive Player of the Year, Comeback Player of the Year, Super Bowl MVP and 1st Team All-Pro.

If you can win it, Tom Brady probably has.

And on Sunday, hell have his chance at illustrious ring number seven, but first, hell have to get through Patrick Mahomes, his presumptive heir apparent as league standard-bearer.

To fully grasp Bradys longevity and consistency (and to see whats changed since he flew south to Tampa), its useful to see his achievements alongside his contemporaries. While others may rival his individual, per-game statistics, its hard to believe that anyone will ever amass the sustained dominance and jaw-dropping rsum that Brady has accrued over the course of his career.

Regardless of outcome, Sundays appearance will put Brady alongside Kareem Abdul-Jabbar as the only American professional team athletes in the last half-century (1971-2020) to play in 10 league finals and win more than half of them. In fact, no other NFL player has been to more than six Super Bowls (Stephen Gostkowski, Mike Lodish).

In addition to his regular attendance to the biggest game of the season, Bradys consistent yearly production over two decades has prompted some to wonder: If you chopped his time in the NFL into twoor even threechunks, would they each be individual Hall of Fame careers?

Story continues

Expected points added (EPA) measures how much better or worse a teams position on the field is from one play to the next; it provides meaningful units to measure a players total contribution to his team. As you can see in the chart below, Bradys seasonal EPA trajectory resembles that of Hall of Fame contemporaries Peyton Manning and Aaron Rodgers if they happened to share one career.

But whats even more stunning about this season is that after two decades with the same coach, owner and home field, Brady joined a new organization in an abbreviated offseason, learned and embraced a new passing philosophy and still managed to rise to the top.

From 2019 to 2020, Brady significantly reduced the frequency of his short throws (<11 air yards)the same ones completed at a league-leading 0.22 EPA/attempt during his time in New Englandand turned to Bruce Arians fabled vertical passing attack. Over the course of the regular season, Brady threw 21 more long passes (25+ yards from the line of scrimmage) than any other player in the league.

Not only is he throwing deep in a way we havent seen before, but hes doing it well; since Week 13, Bradys averaging 0.83 EPA/play on throws 15+ yards from the line of scrimmage, good for fifth in the NFL in that span and just ahead of likely MVP Aaron Rodgers (0.82).

In short, Tom Brady has taken a rsum the size of War and Peace and penned yet another chapter.

More from Sportico.com

Read more here:
Measure of The Man: Tom Bradys Career Numbers Show His Longevity, Versatility - Yahoo Sports

Lewis Hamiltons contract extension for 2021 was one of the least surprising developments of Formula 1s off-season but already some have suggested it may be his last dance. But is that really likely?

Lewis Hamiltons presence within Formula 1s record books is already cemented: most titles (currently held jointly with Michael Schumacher), most wins and most poles, with those figures likely to trickle into triple digits by the summer.

He is continuing to perform at an extraordinary high level as witnessed on a number of occasions in 2020: take your pick from the wet Styrian pole lap, triumphing on three wheels at Silverstone or the drive to seal the title at a grip-less Istanbul Park. There were other less memorable races, such as at Spa, Barcelona or Portimao, at which he merely pulverised the opposition.

Yet there are other statistics that are striking.

Hamilton is already Formula 1s seventh-most experienced driver, his Covid-enforced Sakhir absence concluded the longest streak of appearances at grands prix, while in claiming the title in 2020 he became the oldest champion since Damon Hill in 1996.

The focus, particularly in recent years, has been towards youth. Formula 1s youngest ever champions Fernando Alonso, then Hamilton, then Sebastian Vettel have been followed by its youngest entrant and race winner Max Verstappen whose very arrival prompted a re-writing of the regulations.

Verstappen, who debuted aged 17, is a special case but not quite an anomalous oddity. Contemporaries on the grid, Lance Stroll and Lando Norris, were the second- and fourth-youngest starters in history, while Esteban Ocon comes in at number 11, Charles Leclerc 18 and Carlos Sainz 20, out of the 767 to enter a race. Ferrari has placed its faith in Leclerc, the same age as Verstappen, while George Russell 23 next week has two years under his belt with Williams.

But all still need to displace the mercurial Hamilton, who has previously commented on how he relishes the challenge from the youngsters, from his plinth and there is no reason to expect the World Champion to walk away any time soon.

Every athlete is different but we are in the era of some of the greatest talents in any sport prolonging their astonishing careers beyond what has been widely anticipated some even into their fifth decade. They are special talents, incredible athletes, intensely focused, with an unrelenting rage to win, aided by advancements in science and technology such as a greater appreciation and understanding of elements such as nutrition, training and sleep management. No one path has been the same but the end result has been a train of success.

On Sunday Tom Brady claimed a record seventh Super Bowl title, having transferred from the New England Patriots to the Tampa Bay Buccaneers, aged 43. He has won in three different decades and now has more individual success than any franchise. Last October LeBron James, just nine days older than Hamilton, led the LA Lakers to their first NBA title in 10 years, as well as becoming the Finals MVP.

At our age, we can still dominate our sport, James is quoted by Lakers Daily last month, when referencing Brady. We have one common goal and thats to win and win at the highest level.

Tennis icons Serena Williams and Roger Federer, born seven weeks apart, will turn 40 later this year and both continue to strive to add to trophy cabinets that are overflowing with riches. Federer may currently be recuperating from surgery, and Williams has also struggled with injury, but neither is yet throwing in the towel.

Ive seen players in the locker room, the Legends tour, and at some points I was older than them and I was wondering if I should be there, joked Williams in 2017 on her longevity.

Said Federer recently, to Swiss broadcaster SRF, I like to play tennis for life. In the last few months I have given a lot in rehab. I had to go through it, but I always enjoyed it. I want to celebrate great victories again. And for that, I am ready to go the long, hard road.

Federers long-term rival, Rafael Nadal, is a 13-time French Open champion yet at 34 still hurtles around the court like a caged animal. World Number 1 Novak Djokovic plays with the elasticity of someone a decade younger than his 33 years.

Italys Serie A may not be the most fast-paced of Europes leading football leagues but at the top of the goalscoring charts are Cristiano Ronaldo, 36 exactly a month younger than Hamilton and the enigmatic Zlatan Ibrahimovic, who is 39. Across the Mediterranean the ferocious Luis Suarez, 34, is fronting La Ligas charts. In golf Tiger Woods has not had the sustained success of those just mentioned but his perseverance paid off in 2019, ending an 11-year wait for another major, by claiming the Masters aged 43.

None of this it to say that the athletes in their twenties or even teens and early thirties are lacking in ability, passion or technique. Bradys opposite number on Sunday, Patrick Mahomes, was 24 when he spearheaded Kansas City Chiefs Super Bowl triumph in 2020. NBAs MVP for the last two years, is the Milwaukee Bucks 26-year-old Giannis Antetokounmpo. Naomi Osaka, 23, is already a multi-Grand Slam champion of a talented generation seeking to emulate Williams. Collin Morikawa was 23 when he won last years PGA Championship. In Formula 1 Verstappen and Leclerc who was born on the same day as Osaka have already underlined their credentials. It is a special generation.

But sports GOATs are still going strong and showing little sign of slowing down those who adorned front covers and billboards in the 2000s (or even late 1990s) are still there in the 2020s, pushing away notions of retirement. Moving it closer to home Hamiltons two predecessors as World Champion are Fernando Alonso and Kimi Raikkonen. The returning Alonso, 39, has signed up to compete for Alpine for the next two years while Alfa Romeos Raikkonen, 41, continues to race on, 20 years after their respective Formula 1 bows. Scott Dixon, crowned IndyCar king for a sixth time, is 40, and among his team-mates this year will be NASCAR convert Jimmie Johnson, 45. Valentino Rossi, while no longer a potent front-running force, is still in MotoGP, revered worldwide, and next week turns 42. WRC champion Sebastien Ogier is 37 albeit insisting 2021 will be his swansong.

Hamiltons one-year extension was slightly surprising, given all his past deals have been multi-year arrangements, but there is reason for the relative brevity.

Because we left it very late we wanted to discuss the contract at the end of the season between the Bahrain races and then obviously Lewis didnt feel well, said Mercedes boss Toto Wolff on Monday.

At the end we started our conversations just before Christmas and it was important to get it done as soon as possible and in that respect we thought lets postpone the discussion about 2022 and onwards to a later stage in 2021.

As long as he enjoys racing, I think hes very capable of going longer. He develops as a driver, he looks after himself in terms of physical training and mental preparation side, so I dont think in terms of ability that ends in 2021, but at the end its [his career] his decision.

Hamilton has more to his life than merely Formula 1, most notably his interests in fashion, music, and more recently the push for diversity and equality the campaign for which is more effective the longer he is present. Inevitably, at some point, there will be a generational handover of the baton whether through choice or by circumstance. But his contemporaries have underlined that the older guys can still cut it.

View original post here:
Hamilton, sports GOATs, and the era of longevity - Motorsport Week

When it comes to health, we are all constantly on the lookout for ways to boost our health and overall wellness. Often, we look to food as a means by which to achieve these goals. That seems to make logical sense. Were all constantly told you are what you eat. If that is indeed the case then it is vital that we take a long, hard look at what were putting into our bodies. One food which seems to have an outstanding track record when it comes to health benefits is garlic. Garlic has long been held in high esteem. In fact, the ancient Greek physician Hippocrates apparently used to prescribe garlic for all manner of health conditions. These benefits are not just based on ancient history. Modern science has since confirmed that garlic does in fact benefit the body.

Many of us enjoy the addition of garlic in meals like pizza, pasta and stir fry. But the benefits of adding garlic to your food might be more far-reaching than simply making your food taste good.

Garlic, relative to its small size and calorie content is incredibly nutritious. According to Healthline, just one clove of garlic contains:

And this same amount contains just 4.5 calories 0.2 grams of protein and 1 gram of carbs. It seems that garlic contains a little of almost every single nutrient which the body requires. This means that garlic is nutrient-dense without being calorie-dense. Making it one of the few options for adding flavour without excess calories.

Garlic, mostly in the form of supplements have long been used to boost the immune system. This is something we could all benefit from in 2021 whilst

Heart attacks and strokes are currently some of the worlds leading killers. These diseases are largely causedby high blood pressure (hypertension). Garlic, again in supplement form, seems to have a significant impact on reducing blood pressure. One study found that 6001,500 mg of aged garlic extract was as effective for reducing blood pressure as the drug Atenolol over a 24 week period. The dosage to achieve this effect is quite high and equates to about 4 cloves of garlic a day.

There are two types of cholesterol, one is good and one is bad. LDL is the bad one and HDL is the good type of cholesterol. In sufferers of high cholesterol, taking garlic supplements reduced the total and/or LDL cholesterol by up to 15%. Garlic appears to have a direct impact on LDL cholesterol and works to lower it but has no effect on the good HDL cholesterol.

Garlic is full of antioxidants that aid in supporting the body to protect against oxidative damage. Oxidative damage comes from free radicals and contributes to the ageing process. Garlic supplements have been shown to increase antioxidant enzymes. They also reduce significantly oxidative stress in people with high blood pressure. The combination of reducing cholesterol and blood pressure alongside the antioxidants is hugely important. Studies have shown that it may be beneficial in reducing the risk of brain diseases such as Alzheimers and dementia. It is worth mentioning however that again, these benefits only come from a high dosage of garlic supplements.

The addition of garlic or garlic supplements into the diet seems to have an overall beneficial impact on humans. However, its almost impossible to prove that garlic helps you live longer. What it does do is decrease risk factors such as high blood pressure and high LDL cholesterol. The fact that it aids the immune system also seems to indicate that overall, garlic can have a beneficial impact on the body which may help you live a longer, healthier life.

https://www.healthline.com/nutrition/11-proven-health-benefits-of-garlic#TOC_TITLE_HDR_4

https://www.medicalnewstoday.com/articles/265853

See more here:
Could garlic help to increase your longevity? - Longevity LIVE

Healthy lifestyle: Physical activities abound on college campuses like William & Mary. These healthy habits are among the benefits of college education that contribute to health and longevity, according to a study led by W&M Assistant Professor of Economics Peter Savelyev. Photo by Jim Agnew

by Nathan Warters | February 4, 2021

A study led by William & Mary Assistant Professor of Economics Peter Savelyev and funded by the National Science Foundation argues that college education leads to healthier and longer lives.

The study, Understanding the Mechanisms Linking College Education with Longevity, was published in September in Journal of Human Capital.

Researchers around the world still debate whether education affects health. Savelyev and his team support the claim that education improves heath by demonstrating the mechanisms behind this effect while using state-of-the art statistical analysis.

In our paper, we show that education increases health and longevity though healthier lifestyles, superior earnings and better work conditions, he said.

Savelyev and his co-authors examined data obtained from men and women who graduated from high school in Wisconsin in 1957. This specific timeframe was important to allow for data collection on at least a partially deceased U.S. cohort.

William & Mary News recently spoke to Savelyev about this study. The interview has been edited for length and clarity.

Variables related to healthy lifestyles that proved to be important are participating in physical exercise, maintaining a healthy body weight and abstaining from smoking tobacco. We also study the role of extremely dangerous work conditions, such as cutting trees or being exposed to infectious diseases. Educated people are less likely to face such jobs. The work conditions mechanism does not necessarily imply diminishing job-related risks for the general population, but it is a personal benefit for those who study hard and receive advanced degrees.

It is well known that many essential life determinants emerge early in life. Later in life, things are harder to change. College education is a powerful contributor to human development that increases health and longevity, among many other good effects, and it should be supported in situations when free market solutions do not work well enough.

Our simulations demonstrate that major health differences created by college education are hard to close later in life, even by strong hypothetical policy interventions, such as greatly increasing taxation of cigarettes.

Partly, this is because the effect of education is strong, and it works through many different mechanisms. It is not easy for an intervention that targets just one specific mechanism to overcome a strong effect created through dozens of mechanisms. Also, some policies, such as taxation of cigarettes, affect behavior of both the college-educated and those who did not go to college, so the effect on the difference between these two groups is small.

We find that obtaining a bachelors degree leads to about three additional years of life for men. However, we could not find any effect of college education for women, who live longer than men regardless of their education status. We identified from our data two mechanisms that partly explain the gender difference. One is that men tend to take more dangerous jobs than women. Another is that educated women of this historic cohort born in late 1930s in Wisconsin were less likely to be married, which created a negative contribution to their longevity that masked a positive contribution related to higher income. Marriage is good for your longevity. Since a negative effect of college education on marriage no longer takes place for more recent cohorts of women, we can expect a stronger effect of college on their longevity, as confirmed by our simulations.

Read the rest here:
Study examines why college education leads to healthier and longer lives - William & Mary News

A total of 1trn of defined benefit (DB) pension longevity risk will be insured through de-risking transactions by the end of 2031, Hymans Robertson has predicted.

According it the firms 2021 Risk Transfer Report, buy-ins, buyouts and longevity swaps have insured 0.3trn of risk from DB pension schemes since 2007. This is expected to increase by 0.7trn between now and the end of 2031.

Around 180bn of the 0.3trn came through buy-ins and buyouts, while approximately 110bn was insured through longevity swaps.

Hymans Robertson estimated that around 450bn of the 0.7trn of growth up to 2031 will be driven by buy-ins and buyouts at an average of over 40bn per year.

The remainder of the increase is expected to come through longevity swaps.

Commenting on the findings, Hymans Robertson head of risk transfer, James Mullins, said: 1trn of insurance would be equivalent to around half of the value of all gilts currently issued by the UK government or around half the value of all of the companies in the FTSE 100.

Indeed, with the level of growth in pension scheme buy-ins and buyouts that we are projecting, we can expect to see several insurance companies become some of the largest companies in the FTSE 100 over the next 10 years.

Our analysis projects when each individual DB pension scheme in the UK is expected to be able to afford to insure its pension promises.These projections show that we expect demand from pension schemes for buy-ins and buyouts to average at over 40bn a year during the next decade.

This is due to a combination of factors such as funding requirements meaning that sponsoring employers will need to fund pension schemes to a higher level and the cost of insuring deferred member liabilities having reduced materially in recent years. These points mean that the additional money a pension scheme needs to get to buyout is less than it has been in the past.

This gap will reduce further as pension schemes mature, as more contributions are paid in and as investment risk is reduced further.

Mullins added that the longevity risk associated with around 17 per cent of all DB liabilities in the UK has now been insured, up from around 1 per cent 10 years ago.

During 2020, approximately 54bn of DB pension risk was transferred to insurers, with around 30bn coming form buy-ins and buyouts, and approximately 24bn from longevity swaps, making 2020 the second-highest total on record, after 2019.

Excerpt from:
DB pension de-risking expected to total 1trn by 2031 - Pensions Age

There are three hormones in your body specifically important for healthy aging and longevity. Although for many it seems we shouldnt focus on healthy aging when we are in our 20s and 30s but before you know it, the daily decisions that you are making matter and have a long-term impact on your health.

Many age-related conditions appear out of nowhere. They silently grow inside you before they are apparent and hard to ignore. Thats why regular check-ups and looking underneath the hood once in a while is important.

Well, all hormones matter for healthy aging but here we are going to focus on the three most important hormones for longevity and a healthy lifestyle.

Three Hormones to Focus on for Longevity and Healthy Aging: Which Hormones Matter for Healthy Aging?

Many experts would agree that cortisol is one of the most important ones. Its crucial for your health to keep the level of cortisol low. When your cortisol level is constantly high, it can have many causes namely inflammation, chronic stress, poor sleep, weight gain, and many other reasons. A high level of cortisol is an indicator that you are in a vicious cycle of issues and problems that are accumulating daily.

Cortisol can affect our muscle mass. The important part of healthy aging is keeping your muscles and bones strong. When the level of cortisol is high, it can have an impact on your muscles and bones as well as your overall health.

There are many ways of lowering the level of cortisol. You need to get enough sleep, exercise, learn to relax through methods that suit you from meditation to walking, and learn how to deal with stress. The most important thing is to have more fun in life, less stress. You can also lower the level of cortisol by taking certain supplements such as fish oil but overall healthy lifestyle habits will take you to longevity, healthy aging, and low cortisol levels.

This hormone is crucial for building muscles. When the level of testosterone is low it can be linked to age-related diseases. Older men with a low level of testosterone can have a high risk of death from heart disease. Its important to stress there is a link between testosterone and age since every man loses anywhere between 1% and 2% of testosterone during his life span. If your testosterone level stays higher with age you are in theory younger compared to your peers.

Most of the research on testosterone has been done on men since women naturally have a lower level of testosterone. However, testosterone is important for both genders especially in link with cortisol.

We need to find a way to keep a level of testosterone high as much as possible while keeping the level of cortisol low. In that case, you have better chances to build your muscles and stay healthy.

It seems like a logical question to ask, especially if you are a woman. How to have a higher level of testosterone without growing a mustache? Well, you can start with exercise and lift weights, eat more proteins, carbs, and fats. If you minimize stress and have a low level of cortisol, you will have a higher level of testosterone.

Vitamin D is essential for almost any function from regulating the production of thyroid hormones to helping the immune system and managing inflammation. When we talk about the immune system, some research has been done indicating that vitamin D can help manage the risks of COVID 19. However, we need more research to find a clear connection.

Vitamin D is so easy to take. Sometimes all you need is one supplement a day. Other things that can help include spending more time in the sun or consuming more seafood and fatty fish such as tuna, oysters, sardines, and mackerel. Your diet matters for vitamin D, so eat more eggs, mushrooms, and seafood. The majority of vitamin D supplements come from animal sources so if you are vegan opt for D2 supplements to get enough vitamin D.

There is much that can be done to keep healthy and to optimize your health over the years and keeping track of these hormones is a crucial part of it.

Original post:
Three Hormones to Focus on for Longevity and Healthy Aging - Gildshire Magazines

LAUPHEIM, Germany and STEVENAGE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that the Company is establishing a Center of Excellence for cell and gene therapy, which will be located in Stevenage, UK. With the newly formed UK subsidiary, Rentschler ATMP Ltd., the CDMO will establish development and manufacturing capability in Advanced Therapy Medicinal Products (ATMPs). The Companys UK site is being set up at an already existing facility run by the Cell and Gene Therapy Catapult (CGT Catapult) through a unique collaborative model. Over the next five years, Rentschler Biopharma plans to make a significant investment at the site to set up state-of-the-art manufacturing of viral vectors for clinical supply and expects to be ready for cGMP manufacturing by the first half of 2022.

Dr. Frank Mathias, CEO of Rentschler Biopharma, said: With more than 1000 cell and gene therapies currently in clinical development, the demand for manufacturing capabilities and support is ever increasing. Leveraging our specific expertise in process development and manufacturing for challenging molecules with highest quality and within demanding timelines, we are ideally suited to implement this knowledge in the field of viral vector production for new modalities. Our well-planned move into this growing area of biopharmaceuticals fits well with our strategic plans to expand internationally ensuring proximity to our clients and important biopharma hubs.

Rentschler Biopharma will continue its well-established practice of forming true partnerships with its clients. At this new Center of Excellence, the company plans to partner with entrepreneurial players to enable them to transform their ideas into real products with the potential to treat and even cure patients with serious and life-threatening diseases. Rentschler Biopharma utilizes a highly flexible business model that addresses the specific needs of each client.

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees, headquartered in Laupheim, Germany with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit http://www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

See more here:
Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK - GlobeNewswire

Feb. 10, 2021 08:00 UTC

AMSTERDAM--(BUSINESS WIRE)-- VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today announces its official launch. The Company has been operational since October 2020 and has established its laboratories and offices at the Amsterdam Science Park in The Netherlands.

VectorY develops proprietary and partnered programs based on a novel AAV platform and innovative antibody-based targeted degradation technologies. The Company is creating a pipeline of innovative vectorized antibodies targeting muscular and CNS diseases, aimed at overcoming limitations of current therapies, specifically by improving delivery, durability and accessibility of targeted tissues and cells. These novel viral vectors will have enhanced properties of non-immunogenicity, cell type specificity and expression in selected sub-cellular compartments, thus unlocking new treatment opportunities in these disease areas.

This year, the Company is setting up its own state-of-the-art GMP manufacturing facilities in Amsterdam. Its technology platform will be developed for scalability and yield, with the aim of significantly lowering the costs of advanced gene therapies.

VectorY has already negotiated its first corporate collaboration agreement, gaining access to a highly relevant neuro-inflammation target to develop a vectorized antibody therapy for treatment of neurological disorders. VectorY will continue to consider further collaborations in parallel to progressing its proprietary programs.

The highly experienced management team will be led by Marco Boorsma, General Partner at Forbion, who is joining the management team as Interim CEO. Co-founders Carlo Incerti, Pavlina Konstantinova, Anthony Newcombe, and Barbara Sanders all bring significant longstanding experience in gene therapy, vector development, and biopharmaceutical manufacturing expertise. Carlo Incerti, Operating Partner at Forbion and previously Chief Medical Officer of Sanofi Genzyme, will join VectorYs board as Chairman, together with Sander Slootweg, Managing Partner at Forbion, as board member.

VectorY was seeded by Forbion, following previous investments in successful gene vector companies including bluebird bio (then named Genetix), Biovex, Hookipa, EnGene, Amsterdam Molecular Therapeutics, uniQure and Replimune.

Carlo Incerti, Co-Founder and Chairman of the Board of VectorY, said: I have been working in the gene therapy field for over 30 years, and, from experience, know that accurately targeting the right cells with the transgene has always been of paramount importance. Using viral vectors developed at VectorY to deliver the genetic sequence for therapeutic antibody expression in target cells has the potential to address some of the key shortcomings of intravenously injected molecules. Our aim is to create novel treatments for patients.

Marco Boorsma, Interim CEO of VectorY, said: VectorY is developing innovative technologies to create novel, potentiated vectorized antibodies that will target muscle and CNS disorders, for which substantial unmet medical needs exist. Our aim is to bring new, powerful treatments to patients suffering from serious diseases. The Company is hitting the ground running, capitalizing on the extensive experience of the co-founders, and the support and expertise from Forbion as a longstanding gene therapy investor.

-Ends-

Notes to Editors

About VectorY VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for muscular and neurodegenerative diseases with high unmet medical need.

Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted degradation technologies, and proprietary manufacturing technology.

VectorY develops proprietary & partnered programs and product candidates are based on new technologies that will enable the next generation of highly scalable manufacturing processes within VectorYs own manufacturing facilities. VectorYs manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

About Forbion Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space.

Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbions current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 69 companies.

The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.

Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, ERP Venture Capital Fonds investments. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

For more information, please visit: http://www.forbion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005065/en/

Continued here:
Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies - BioSpace

New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026" - https://www.reportlinker.com/p06021776/?utm_source=GNW

The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.

The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period: CMOs Offering Vector Manufacturing Services for Cell and Gene Therapy Companies Robust Cell & Gene Therapies in the Pipeline Increase in Strategic Acquisitions Regulatory Support for Cell and Gene Therapy Products

The study considers the present scenario of the Europe cell and gene therapy market and its market dynamics for the period 2020?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Europe Cell and Gene Therapy Market Segmentation The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.

Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.

Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patients quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.

Product Cell Therapies Gene Therapies End-user Hospitals Cancer Care Centers Wound Care Centers Others Application Oncology Dermatology Musculoskeletal Others

INSIGHTS BY GEOGRAPHY Germany, France, the UK, Italy, and Spain play a significant role in the Europe cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. In addition, the target patient population is increasing across Europe; there were an estimated 3.9 million new cases of cancer and 1.9 million cancer deaths in Europe in 2018. In addition, the prevalence surveys in the UK and Denmark indicate that there are 34 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes that are involved in the development of cell and gene therapies are expected to boosting the market in Europe.

Geography Europe o UK o Germany o France o Italy o Spain o Switzerland o Netherlands

INSIGHTS BY VENDORS Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors. While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.

Prominent Vendors Novartis Spark Therapeutics Amgen Gilead Sciences Organogenesis

Other Prominent Vendors APAC Biotech AVITA Medical bluebird bio CHIESI Farmaceutici CollPlant CO.DON Human Stem Cells Institute PJSC (HSCI) Medipost NuVasive Nipro Orchard Therapeutics RMS Regenerative Medical System Orthocell Osiris Therapeutics Sibino GeneTech Shanghai Sunway Biotech Takeda Pharmaceutical Company Terumo Vericel

Emerging Investigational Vendors In Europe Adaptimmune Therapeutics AgenTus Therapeutics Autolus Cellecits Celyad CombiGene EUKARS Freeline Therapeutics Innoskel PsiOxus Therapeutics Ltd SparingVision uniQure

KEY QUESTIONS ANSWERED 1. What is the Europe cell and gene therapy market size and growth rate during the forecast period? 2. What are the factors driving the demand for CAR-T therapy in the European region? 3. How are strategic acquisitions aiding in market growth of cell and gene therapy products? 4. Which segments are expected to generate the highest revenues during the forecast period? 5. Who are the leading vendors in the European cell and gene therapy market?Read the full report: https://www.reportlinker.com/p06021776/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post here:
The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 20212026 - GlobeNewswire